Necrotizing soft-tissue infections

New England Journal of Medicine

Volumn 377, Issue 23, 2017, Pages 2253-2265

  Stevens, Dennis L ^b   Bryant, Amy E ^a  

^a Boise VA Medical Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; NONSTEROID ANTIINFLAMMATORY AGENT; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN;

BIOPSY; CAPILLARY LEAK SYNDROME; CARDIOMYOPATHY; CLINICAL FEATURE; CLOSTRIDIUM INFECTION; CRITICALLY ILL PATIENT; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE MARKER; EARLY DIAGNOSIS; GAS GANGRENE; GRAM STAINING; GROUP A STREPTOCOCCAL INFECTION; HISTOLOGY; HUMAN; HYPERBARIC OXYGEN THERAPY; INTRAVASCULAR HEMOLYSIS; MORTALITY; NECROTIZING FASCIITIS; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOFT TISSUE INFECTION; THERAPY DELAY; BLOOD; CHEMICALLY INDUCED; CRITICAL ILLNESS; DEBRIDEMENT; PATHOLOGY; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOMARKERS; BIOPSY; C-REACTIVE PROTEIN; CRITICAL ILLNESS; DEBRIDEMENT; FASCIITIS, NECROTIZING; GAS GANGRENE; HUMANS; HYPERBARIC OXYGENATION; IMMUNOGLOBULINS, INTRAVENOUS; SOFT TISSUE INFECTIONS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 85038239247     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1600673     Document Type: Review

References (100)

1. Pasternack MS, Swartz MN. Cellulitis, necrotizing fasciitis, and subcutaneous tissue infections. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and practice of infectious diseases. 8th ed. Philadelphia: Elsevier, 2015: 1194-215.
2. Khamnuan P, Chongruksut W, Jearwattanakanok K, Patumanond J, Tantraworasin A. Necrotizing fasciitis: epidemiology and clinical predictors for amputation. Int J Gen Med 2015; 8: 195-202.
3. Naseer U, Steinbakk M, Blystad H, Caugant DA. Epidemiology of invasive group A streptococcal infections in Norway 2010-2014: a retrospective cohort study. Eur J Clin Microbiol Infect Dis 2016; 35: 1639-48.
4. Glass GE, Sheil F, Ruston JC, Butler PE. Necrotising soft tissue infection in a UK metropolitan population. Ann R Coll Surg Engl 2015; 97: 46-51.
5. Bocking N, Matsumoto CL, Loewen K, et al. High incidence of invasive group A streptococcal infections in remote indigenous communities in northwestern Ontario, Canada. Open Forum Infect Dis 2016; 4(1): ofw243.
6. Jabbour G, El-Menyar A, Peralta R, et al. Pattern and predictors of mortality in necrotizing fasciitis patients in a single tertiary hospital. World J Emerg Surg 2016; 11: 40.
7. Nordqvist G, Wallden A, Brorson H, Tham J. Ten years of treating necrotizing fasciitis. Infect Dis (Lond) 2015; 47: 319-25.
8. McHenry CR, Piotrowski JJ, Petrinic D, Malangoni MA. Determinants of mortality for necrotizing soft-tissue infections. Ann Surg 1995; 221: 558-63.
9. van Stigt SF, de Vries J, Bijker JB, et al. Review of 58 patients with necrotizing fasciitis in the Netherlands. World J Emerg Surg 2016; 11: 21.
10. Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am 2003; 85-A: 1454-60.
11. Devaney B, Frawley G, Frawley L, Pilcher DV. Necrotising soft tissue infections: the effect of hyperbaric oxygen on mortality. Anaesth Intensive Care 2015; 43: 685-92.
12. Kulasegaran S, Cribb B, Vandal AC, McBride S, Holland D, MacCormick AD. Necrotizing fasciitis: 11-year retrospective case review in South Auckland. ANZ J Surg 2016; 86: 826-30.
13. Suzuki K, Hayashi Y, Otsuka H, et al. Case report: a case of Lemierre's syndrome associated with necrotizing fasciitis and septic embolization. Nihon Naika Gakkai Zasshi 2016; 105: 99-104. (In Japanese.)
14. Tawa A, Larmet R, Malledant Y, Seguin P. Severe sepsis associated with Lemierre's syndrome: a rare but lifethreatening disease. Case Rep Crit Care 2016; 2016: 1264283.
15. Luckett WH. VII. Large phagedenic ulcer of the abdomen. Ann Surg 1909; 50: 605-8.
16. Arif N, Yousfi S, Vinnard C. Deaths from necrotizing fasciitis in the United States, 2003-2013. Epidemiol Infect 2016; 144: 1338-44.
17. Cheng NC, Wang JT, Chang SC, Tai HC, Tang YB. Necrotizing fasciitis caused by Staphylococcus aureus: the emergence of methicillin-resistant strains. Ann Plast Surg 2011; 67: 632-6.
18. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillinresistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352: 1445-53.
19. Tsai YH, Shen SH, Yang TY, Chen PH, Huang KC, Lee MS. Monomicrobial necrotizing fasciitis caused by Aeromonas hydrophila and Klebsiella pneumoniae. Med Princ Pract 2015; 24: 416-23.
20. Yahav D, Duskin-Bitan H, Eliakim- Raz N, et al. Monomicrobial necrotizing fasciitis in a single center: the emergence of Gram-negative bacteria as a common pathogen. Int J Infect Dis 2014; 28: 13-6.
21. Lee CY, Kuo LT, Peng KT, Hsu WH, Huang TW, Chou YC. Prognostic factors and monomicrobial necrotizing fasciitis: gram-positive versus gram-negative pathogens. BMC Infect Dis 2011; 11: 5.
22. Sims SA, Colquhoun S, Wyber R, Carapetis JR. Global disease burden of group A streptococcus. In: Ferretti JJ, Stevens DL, Fischetti VA, eds. Streptococcus pyogenes: basic biology to clinical manifestations. Oklahoma City: University of Oklahoma Health Sciences Center, 2016: 19785-8.
23. Hamilton SM, Stevens DL, Bryant AE. Pregnancy-related group a streptococcal infections: temporal relationships between bacterial acquisition, infection onset, clinical findings, and outcome. Clin Infect Dis 2013; 57: 870-6.
24. Nelson GE, Pondo T, Toews KA, et al. Epidemiology of invasive group A streptococcal infections in the United States, 2005-2012. Clin Infect Dis 2016; 63: 478-86
25. Lepoutre A, Doloy A, Bidet P, et al. Epidemiology of invasive Streptococcus pyogenes infections in France in 2007. J Clin Microbiol 2011; 49: 4094-100.
26. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321: 1-7.
27. Wong CJ, Stevens DL. Serious group A streptococcal infections. Med Clin North Am 2013; 97: 721-736, xi-xii.
28. Adams EM, Gudmundsson S, Yocum DE, Haselby RC, Craig WA, Sundstrom WR. Streptococcal myositis. Arch Intern Med 1985; 145: 1020-3.
29. Nuwayhid ZB, Aronoff DM, Mulla ZD. Blunt trauma as a risk factor for group A streptococcal necrotizing fasciitis. Ann Epidemiol 2007; 17: 878-81.
30. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334: 240-5.
31. Schurr M, Engelhardt S, Helgerson R. Limb salvage for streptococcal gangrene of the extremity. Am J Surg 1998; 175: 213-7.
32. Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis 2007; 44: 705-10.
33. Brogan TV, Nizet V, Waldhausen JHT, Rubens CE, Clarke WR. Group A streptococcal necrotizing fasciitis complicating primary varicella: a series of fourteen patients. Pediatr Infect Dis J 1995; 14: 588-94.
34. Outbreak of invasive group A streptococcus associated with varicella in a childcare center - Boston, Massachusetts, 1997. MMWR Morb Mortal Wkly Rep 1997; 46: 944-8.
35. Laupland KB, Davies HD, Low DE, Schwartz B, Green K, McGeer A. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Pediatrics 2000; 105: E60.
36. Zakikhany K, Degail MA, Lamagni T, et al. Increase in invasive Streptococcus pyogenes and Streptococcus pneumoniae infections in England, December 2010 to January 2011. Euro Surveill 2011; 16: 19785.
37. Zachariadou L, Stathi A, Tassios PT, Pangalis A, Legakis NJ, Papaparaskevas J. Differences in the epidemiology between paediatric and adult invasive Streptococcus pyogenes infections. Epidemiol Infect 2014; 142: 512-9.
38. Meleney FL. Hemolytic streptococcus gangrene. Arch Surg 1924; 9: 317-64.
39. Stevens DL. Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin Infect Dis 1995; 21: 977-80.
40. Aronoff DM, Bloch KC. Assessing the relationship between the use of nonsteroidal antiinflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine (Baltimore) 2003; 82: 225-35.
41. Lesko SM. The safety of ibuprofensuspension in children. Int J Clin Pract Suppl 2003; 135: 50-3.
42. Lamagni TL, Neal S, Keshishian C, et al. Severe Streptococcus pyogenes infections, United Kingdom, 2003-2004. Emerg Infect Dis 2008; 14: 202-9.
43. Dubos F, Hue V, Grandbastien B, Catteau B, Martinot A. Bacterial skin infections in children hospitalized with varicella: a possible negative impact of non-steroidal anti-inflammatory drugs? Acta Derm Venereol 2008; 88: 26-30.
44. Mikaeloff Y, Kezouh A, Suissa S. Nonsteroidal anti-inflammatory drug use and the risk of severe skin and soft tissue complications in patients with varicella or zoster disease. Br J Clin Pharmacol 2008; 65: 203-9.
45. Leroy S, Marc E, Bavoux F, et al. Hospitalization for severe bacterial infections in children after exposure to NSAIDs: a prospective adverse drug reaction reporting study. Clin Drug Investig 2010; 30: 179-85
46. Das DK, Baker MG, Venugopal K. Risk factors, microbiological findings and outcomes of necrotizing fasciitis in New Zealand: a retrospective chart review. BMC Infect Dis 2012; 12: 348.
47. Hamilton SM, Bayer CR, Stevens DL, Bryant AE. Effects of selective and nonselective nonsteroidal anti-inflammatory drugs on antibiotic efficacy of experimental group A streptococcal myonecrosis. J Infect Dis 2014; 209: 1429-35.
48. Weng TC, Chen CC, Toh HS, Tang HJ. Ibuprofen worsens Streptococcus pyogenes soft tissue infections in mice. J Microbiol Immunol Infect 2011; 44: 418-23.
49. Hamilton SM, Bayer CR, Stevens DL, Lieber RL, Bryant AE. Muscle injury, vimentin expression, and nonsteroidal antiinflammatory drugs predispose to cryptic group A streptococcal necrotizing infection. J Infect Dis 2008; 198: 1692-8.
50. Stevens DL, Laposky LL, McDonald P, Harris I. Spontaneous gas gangrene at a site of remote injury - localization due to circulating antitoxin. West J Med 1988; 148: 204-5.
51. Stevens DL. Clostridial myonecrosis and other clostridial diseases. In: Bennett JC, Plum F, eds. Cecil textbook of medicine. 20th ed. Philadelphia: W.B. Saunders, 1996: 2090-3.
52. Fleming A. On the bacteriology of septic wounds. Lancet 1915; 186: 638-43.
53. MacLennan JD. The histotoxic clostridial infections of man. Bacteriol Rev 1962; 26: 177-276.
54. Stewart JC. Anaerobic cellulitis. J Am Med Assoc 1905; 45: 528-35.
55. Qvist G. Anaerobic cellulitis and gas gangrene. Br Med J 1941; 2: 217-21.
56. Bodey GP, Rodriguez S, Fainstein V, Elting LS. Clostridial bacteremia in cancer patients: a 12-year experience. Cancer 1991; 67: 1928-42.
57. Stevens DL, Musher DM, Watson DA, et al. Spontaneous, nontraumatic gangrene due to Clostridium septicum. Rev Infect Dis 1990; 12: 286-96.
58. Aldape MJ, Bryant AE, Stevens DL. Clostridium sordellii infection: epidemiology, clinical findings, and current perspectives on diagnosis and treatment. Clin Infect Dis 2006; 43: 1436-46.
59. Alayed KA, Tan C, Daneman N. Red flags for necrotizing fasciitis: a case control study. Int J Infect Dis 2015; 36: 15-20.
60. Carbonetti F, Cremona A, Carusi V, et al. The role of contrast enhanced computed tomography in the diagnosis of necrotizing fasciitis and comparison with the Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC). Radiol Med 2016; 121: 106-21.
61. Stamenkovic I, Lew PD. Early recognition of potentially fatal necrotizing fasciitis - the use of frozen-section biopsy. N Engl J Med 1984; 310: 1689-93.
62. Majeski J, Majeski E. Necrotizing fasciitis: improved survival with early recognition by tissue biopsy and aggressive surgical treatment. South Med J 1997; 90: 1065-8.
63. Chelsom J, Halstensen A, Haga T, Hoiby EA. Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 1994; 344: 1111-5.
64. Wall DB, Klein SR, Black S, de Virgilio C. A simple model to help distinguish necrotizing fasciitis from nonnecrotizing soft tissue infection. J Am Coll Surg 2000; 191: 227-31.
65. Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med 2004; 32: 1535-41.
66. Bechar J, Sepehripour S, Hardwicke J, Filobbos G. Laboratory Risk Indicator for Necrotising Fasciitis (LRINEC) score for the assessment of early necrotising fasciitis: a systematic review of the literature. Ann R Coll Surg Engl 2017; 99: 341-6.
67. Burner E, Henderson SO, Burke G, Nakashioya J, Hoffman JR. Inadequate sensitivity of laboratory risk indicator to rule out necrotizing fasciitis in the emergency department. West J Emerg Med 2016; 17: 333-6.
68. Holland MJ. Application of the Laboratory Risk Indicator in Necrotising Fasciitis (LRINEC) score to patients in a tropical tertiary referral centre. Anaesth Intensive Care 2009; 37: 588-92.
69. Putnam LR, Richards MK, Sandvall BK, Hopper RA, Waldhausen JH, Harting MT. Laboratory evaluation for pediatric patients with suspected necrotizing soft tissue infections: a case-control study. J Pediatr Surg 2016; 51: 1022-5.
70. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59(2): e10-e52.
71. Bandyopadhyay D, Jacobs JV, Panchabhai TS. What's new in emergencies, trauma and shock? The tortuous path in the management of necrotizing fasciitis: is early surgical intervention critical? J Emerg Trauma Shock 2016; 9: 1-2.
72. Hakkarainen TW, Kopari NM, Pham TN, Evans HL. Necrotizing soft tissue infections: review and current concepts in treatment, systems of care, and outcomes. Curr Probl Surg 2014; 51: 344-62.
73. Crew JR, Varilla R, Allandale Rocas T III, Abdul Rani S, Debabov D. Treatment of acute necrotizing fasciitis using negative pressure wound therapy and adjunctive NeutroPhase irrigation under the foam. Wounds 2013; 25: 272-7.
74. Baharestani MM. Negative pressure wound therapy in the adjunctive management of necrotizing fasciitis: examining clinical outcomes. Ostomy Wound Manage 2008; 54: 44-50.
75. Lee JY, Jung H, Kwon H, Jung SN. Extended negative pressure wound therapyassisted dermatotraction for the closure of large open fasciotomy wounds in necrotizing fasciitis patients. World J Emerg Surg 2014; 9: 29.
76. Freischlag JA, Ajalat G, Busuttil RW. Treatment of necrotizing soft tissue infections: the need for a new approach. Am J Surg 1985; 149: 751-5.
77. Bucca K, Spencer R, Orford N, Cattigan C, Athan E, McDonald A. Early diagnosis and treatment of necrotizing fasciitis can improve survival: an observational intensive care unit cohort study. ANZ J Surg 2013; 83: 365-70.
78. Hadeed GJ, Smith J, O'Keeffe T, et al. Early surgical intervention and its impact on patients presenting with necrotizing soft tissue infections: a single academic center experience. J Emerg Trauma Shock 2016; 9: 22-7.
79. Hawser S, Hoban DJ, Badal RE, et al. Epidemiology and antimicrobial susceptibility of Gram-negative aerobic bacteria causing intra-abdominal infections during 2010-2011. J Chemother 2015; 27: 67-73
80. Satlin MJ, Chen L, Patel G, et al. Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem- resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States. Antimicrob Agents Chemother 2017; 61(4): e02349-16.
81. Krapp F, Grant JL, Sutton SH, Ozer EA, Barr VO. Treating complicated carbapenem- resistant Enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation. Int J Antimicrob Agents 2017; 49: 770-3.
82. DeMuri GP, Sterkel AK, Kubica PA, Duster MN, Reed KD, Wald ER. Macrolide and clindamycin resistance in group A streptococci isolated from children with pharyngitis. Pediatr Infect Dis J 2017; 36: 342-4.
83. Peng XM, Yang P, Liu S, et al. The genetic features of drug resistance to group A streptococcus and macrolides antibiotics among pediatric patients in Beijing 2012. Zhonghua Yu Fang Yi Xue Za Zhi 2013; 47: 1040-4. (In Chinese.)
84. Lewis JS II, Lepak AJ, Thompson GR III, et al. Failure of clindamycin to eradicate infection with beta-hemolytic streptococci inducibly resistant to clindamycin in an animal model and in human infections. Antimicrob Agents Chemother 2014; 58: 1327-31.
85. Bryant AE, Aldape MJ, Bayer CR, McIndoo E, Stevens DL. Efficacy of tedizolid in experimental myonecrosis caused by erythromycin/ clindamycin-sensitive and -resistant group A streptococcus. In: Proceedings and Abstracts of 2016 IDWeek, New Orleans, October 26-30, 2016.
86. Stevens DL, Maier KA, Laine BM, Mitten JE. Comparison of clindamycin, rifampin, tetracycline, metronidazole, and penicillin for efficacy in prevention of experimental gas gangrene due to Clostridium perfringens. J Infect Dis 1987; 155: 220-8.
87. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017; 43: 304-77.
88. Stevens DL, Shelly MP, Stiller R, Villasenor- S A, Bryant AE. Acute reversible cardiomyopathy in patients with streptococcal toxic shock syndrome. In: Proceedings of the XVIIth Lancefield International Symposium on Streptococci and Streptococcal Diseases, Athens, June 22-26, 2008.
89. Wang C, Schwaitzberg S, Berliner E, Zarin DA, Lau J. Hyperbaric oxygen for treating wounds: a systematic review of the literature. Arch Surg 2003; 138: 272-9.
90. Jallali N, Withey S, Butler PE. Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis. Am J Surg 2005; 189: 462-6.
91. Willy C, Rieger H, Vogt D. Hyperbaric oxygen therapy for necrotizing soft tissue infections: contra. Chirurg 2012; 83: 960-72 (In German.)
92. Shaw JJ, Psoinos C, Emhoff TA, Shah SA, Santry HP. Not just full of hot air: hyperbaric oxygen therapy increases survival in cases of necrotizing soft tissue infections. Surg Infect (Larchmt) 2014; 15: 328-35.
93. Stevens DL, Bryant AE, Adams K, Mader JT. Evaluation of hyperbaric oxygen therapy for treatment of experimental Clostridium perfringens infection. Clin Infect Dis 1993; 17: 231-7.
94. Hansen MB, Simonsen U, Garred P, Hyldegaard O. Biomarkers of necrotising soft tissue infections: aspects of the innate immune response and effects of hyperbaric oxygenation - the protocol of the prospective cohort BIONEC study. BMJ Open 2015; 5(5): e006995.
95. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. Clin Infect Dis 1999; 28: 800-7.
96. Darenberg J, Ihendyane N, Sjolin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37: 333-40.
97. Shah SS, Hall M, Srivastava R, Subramony A, Levin JE. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis 2009; 49: 1369-76.
98. Linner A, Darenberg J, Sjolin J, Henriques- Normark B, Norrby-Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 2014; 59: 851-7.
99. Kadri SS, Swihart BJ, Bonne SL, et al. Impact of intravenous immunoglobulin on survival in necrotizing fasciitis with vasopressor-dependent shock: a propensity score-matched analysis from 130 US hospitals. Clin Infect Dis 2017; 64: 877-85
100. Bulger EM, Maier RV, Sperry J, et al. A novel drug for treatment of necrotizing soft-tissue infections: a randomized clinical trial. JAMA Surg 2014; 149: 528-36.